Literature DB >> 11466313

The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate.

R Yan1, P Han, H Miao, P Greengard, H Xu.   

Abstract

Release of Abeta peptides from beta-amyloid precursor protein (APP) requires sequential cleavage by two endopeptidases, beta- and gamma-secretases. beta-Secretase was recently identified as a novel membrane-bound aspartyl protease, named BACE1, Asp2, or memapsin 2. Employing confocal microscopy and subcellular fractionation, we have found that BACE1 is largely situated in the distal Golgi membrane with a minor presence in the endoplasmic reticulum, endosomes, and plasma membrane in human neuroblastoma SHEP cells and in mouse Neuro-2a cell lines expressing either endogenous mouse BACE1 or additional exogenous human BACE1. The major cellular beta-secretase activity is located in the late Golgi apparatus, consistent with its cellular localization. Furthermore, we demonstrate that the single transmembrane domain of BACE1 alone determines the retention of BACE1 to the Golgi compartments, through examination of recombinant proteins of various BACE1 fragments fused to a reporter green fluorescence protein. In addition, we show that the transmembrane domain of BACE1 is required for the access of BACE1 enzymatic activity to the cellular APP substrate and hence for the optimal generation of the C-terminal fragment of APP (CTF99). The results suggest a molecular and cell biological mechanism for the regulation of beta-secretase activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466313     DOI: 10.1074/jbc.M104350200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

Review 1.  Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin.

Authors:  Johannes Prox; Andrea Rittger; Paul Saftig
Journal:  Exp Brain Res       Date:  2011-11-27       Impact factor: 1.972

Review 2.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

3.  Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

Authors:  Lujia Zhou; Lucia Chávez-Gutiérrez; Katrijn Bockstael; Ragna Sannerud; Wim Annaert; Patrick C May; Eric Karran; Bart De Strooper
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

4.  Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells.

Authors:  Zoia Muresan; Virgil Muresan
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts.

Authors:  Kulandaivelu S Vetrivel; Xavier Meckler; Ying Chen; Phuong D Nguyen; Nabil G Seidah; Robert Vassar; Philip C Wong; Masaki Fukata; Maria Z Kounnas; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

6.  Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

Authors:  Yaomin Chen; Kun Zhou; Ruishan Wang; Yun Liu; Young-Don Kwak; Tao Ma; Robert C Thompson; Yongbo Zhao; Layton Smith; Laura Gasparini; Zhijun Luo; Huaxi Xu; Francesca-Fang Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

7.  Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase.

Authors:  Diana W Shineman; Aleksandra S Dain; Minkyu L Kim; Virginia M-Y Lee
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

8.  Structural Similarities between Neuregulin 1-3 Isoforms Determine Their Subcellular Distribution and Signaling Mode in Central Neurons.

Authors:  Detlef Vullhorst; Tanveer Ahmad; Irina Karavanova; Carolyn Keating; Andres Buonanno
Journal:  J Neurosci       Date:  2017-04-21       Impact factor: 6.167

9.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities.

Authors:  Xiangyou Hu; Qi Shi; Xiangdong Zhou; Wanxia He; Hong Yi; Xinghua Yin; Marla Gearing; Allan Levey; Riqiang Yan
Journal:  EMBO J       Date:  2007-05-03       Impact factor: 11.598

Review 10.  β-Secretase: its biology as a therapeutic target in diseases.

Authors:  Haibo Wang; Rena Li; Yong Shen
Journal:  Trends Pharmacol Sci       Date:  2013-02-27       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.